Ranked by engagement
Top topics — all time page 17
Ranked by replies, likes and views over all time, with a bonus for topics that reached a marked solution. Engagement is a proxy for usefulness and a poor one; the documentation commons is the better index of what is settled.
1,535 topics · page 17 of 40
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Lurking for two months before posting: was that the right call?
Asking directly, because I could not find a straight answer: Lurking for two months before posting: was that the right call? Question in the title. Context below, and I have tried to include the things people…
|
+66 | 71 | 11k | 8mo |
|
How much context is too much context in a first post?
How much context is too much context in a first post? I have a specific reason for asking rather than idle curiosity, and the context is below. Counting it rather than describing it, because the count is the…
|
+69 | 74 | 935 | 18d |
|
Second pass at: LOD and LOQ: definitions people get wrong
Posting this under the heading it deserves: Second pass at: LOD and LOQ: definitions people get wrong Everything below is what sits behind that. Something about LOD and LOQ does not reconcile and I would like…
|
+47 | 51 | 40k | 10mo |
|
Follow-up: A supplier that answers analytical questions with restated claims
A supplier that answers analytical questions with restated claims — setting out what I have, and where I think it stops being reliable. A follow-up question about supplier that I did not know to ask the first…
|
+74 | 82 | 2.8k | 6mo |
|
Second pass at: Regression to the mean in progress reports
Second pass at: Regression to the mean in progress reports Writing it up because I had to work it out twice and would rather nobody else did. Posting a small dataset on Regression. It is mine, it is…
|
+71 | 75 | 4k | 17mo |
|
Electrolyte supplements: which ones do anything
On the subject in the title: Electrolyte supplements: which ones do anything Working notes rather than a conclusion. A hydration and intake question, with the figures, since this one is unanswerable without…
|
+47 | 51 | 31k | 18d |
|
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset
How Janoshik, Medutest, PeptideMeter and VendorInvestigate differ — a second dataset I have a specific reason for asking rather than idle curiosity, and the context is below. Posting a small dataset on…
|
+42 | 46 | 46k | 2mo |
|
Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide
Posting this under the heading it deserves: Revisiting: Semaglutide formulation: what is in the licensed product besides the peptide Everything below is what sits behind that. I have spent a fortnight trying…
|
+72 | 77 | 7.2k | 19mo |
|
Holding a dose indefinitely: is there a documented downside?
Holding a dose indefinitely: is there a documented downside? — that is the question, and I have not found it answered plainly anywhere I have looked. I have read the maintained page on this and I still have a…
|
+28 | 32 | 57k | 12mo |
|
Publishing an inconvenient result: a case study — the long version
Publishing an inconvenient result: a case study — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Publishing an inconvenient result,…
|
+68 | 74 | 12k | 7mo |
|
Second pass at: Journal club: LEADER as the historical anchor
Posting this under the heading it deserves: Second pass at: Journal club: LEADER as the historical anchor Everything below is what sits behind that. Two things I would like separated before anyone answers on…
|
+75 | 81 | 2k | 2y |
|
Coming back to: Research-use-only labelling: what it means and what it does not
Research-use-only labelling: what it means and what it does not — setting out what I have, and where I think it stops being reliable. A labelling question, and I would like the answer to be about what the…
|
+45 | 50 | 39k | 20mo |
|
Programming during a large energy deficit
Programming during a large energy deficit — setting out what I have, and where I think it stops being reliable. Programming during a large energy: what I expected, what I found, and the gap between them. I am…
|
+39 | 49 | 36k | 2d |
|
Injection volume, overload, and peak distortion
Posting this under the heading it deserves: Injection volume, overload, and peak distortion Everything below is what sits behind that. I have spent a fortnight trying to pin injection volume down and I want…
|
+43 | 47 | 36k | 2mo |
|
What "marked as solution" means and who gets to mark it — does this still hold?
What "marked as solution" means and who gets to mark it — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I want to check my reasoning rather…
|
+69 | 74 | 2.4k | 3mo |
|
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
+61 | 65 | 2k | 13mo |
|
Waist circumference technique and its repeatability
Waist circumference technique and its repeatability — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin waist circumference technique down and I want…
|
+55 | 60 | 11k | 5mo |
|
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. Working notes on four-week escalation interval rather than a…
|
+56 | 60 | 21k | 2y |
|
Transporting a vial for a weekend away
On the subject in the title: Transporting a vial for a weekend away Working notes rather than a conclusion. Transporting a vial, and specifically the version of it that the documentation does not cover. The…
|
+39 | 45 | 35k | 21mo |
|
Second pass at: Circumference measurements as a poor man's composition estimate
Second pass at: Circumference measurements as a poor man's composition estimate — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…
|
+64 | 68 | 13k | 4mo |
|
Why fasting instructions for oral semaglutide are not optional advice
Why fasting instructions for oral semaglutide are not optional advice I have a specific reason for asking rather than idle curiosity, and the context is below. Fasting instructions for oral semaglutide, from…
|
+70 | 74 | 1.1k | 23d |
|
Follow-up: The lowest dose that does anything: is that a real question?
The question in the title: The lowest dose that does anything: is that a real question? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this and I still…
|
+70 | 75 | 12k | 8mo |
|
Why "any advice?" is the least effective ending for a post — the long version
Asking directly, because I could not find a straight answer: Why "any advice?" is the least effective ending for a post — the long version Counting it rather than describing it, because the count is the part…
|
+79 | 83 | 1.6k | 9mo |
|
Guidelines revision: what changed and why — one year on
On the subject in the title: Guidelines revision: what changed and why — one year on Working notes rather than a conclusion. A methods question rather than a substantive one, about Guidelines revision.…
|
+73 | 81 | 3.9k | 4mo |
|
Second pass at: The mass-error checker and its intended scope
Posting this under the heading it deserves: Second pass at: The mass-error checker and its intended scope Everything below is what sits behind that. Posting a small dataset on mass-error checker. It is mine,…
|
+70 | 74 | 1.7k | 8mo |
|
Hepatic steatosis: what the MASH trial evidence supports
Hepatic steatosis: what the MASH trial evidence supports — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on hepatic steatosis, before…
|
+77 | 83 | 950 | 13mo |
|
[2026 update] What we do not know about retatrutide, listed explicitly
What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question…
|
+79 | 83 | 952 | 11mo |
|
A checklist for reading a certificate in under two minutes
A checklist for reading a certificate in under two minutes — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere.…
|
+39 | 46 | 38k | 1mo |
|
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. What changes if the standard account of Amylin receptor signalling and satiety…
|
+73 | 78 | 3.5k | 2mo |
|
Coming back to: Getting a referral rather than a refusal
Posting this under the heading it deserves: Getting a referral rather than a refusal Everything below is what sits behind that. Working notes on Getting a referral rather than a conclusion. I would rather…
|
+69 | 74 | 1.7k | 13mo |